Growth Disorders

Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.

Subtype terms (1)

More specific conditions that are subtypes of Growth Disorders in the MeSH hierarchy.

Fetal Growth Retardation
29 drugs (21 approved, 8 experimental)

Drugs by status

Organizations

Organization Involved with Phase 3 Indications (15)

Novo Nordisk
Eli Lilly
Pfizer
Ipsen
DSM
Sponsor GmbH
Versartis Inc.
Keio University
Johns Hopkins University
University of Tampere
International Center for Diarrheal Disease Research
University of Malawi
Government of Finland
Foundation for Paediatric Research, Finland
United Nations

Organization Involved with Phase 2 Indications (2)

National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)

Organization Involved with Phase 1 Indications (2)

University of Rostock
Humboldt University

Organization Involved with Other Experimental Indications (11)

ArQule
Swiss Federal Institute of Technology
Gadjah Mada University
Aga Khan University
University of California, San Francisco
University of Colorado, Denver
Government of Pakistan
Washington University in St. Louis
HarvestPlus
Brac University, Bangladesh
Project Peanut Butter